UVA-1 light treatment for hand skin tightness in scleroderma
Part of Skin clinical trials.
This study tests whether UVA-1 light sessions can loosen tight skin and improve hand function in people with scleroderma. If you qualify, you would attend UVA-1 treatments twice a week for the study period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to understand the study and sign informed consent
- You are age 18 or older
- Your scleroderma affects the skin on both hands about equally
- You can attend UVA-1 sessions twice each week
- Your overall (systemic) scleroderma medicine should not change during the first 100 days
- You should avoid pregnancy during the study period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses ultrasound and nerve tests to look at how systemic sclerosis (scleroderma) affects the hands. It aims to find what causes hand problems and may help improve care for people with this condition.
This trial collects skin samples from people with scleroderma and from healthy volunteers undergoing plastic surgery. Researchers will study the genes in skin cells to better understand the disease.
This study tests whether a person's own fat cells (processed into regenerative cells) can be injected into the hands to improve hand function and reduce skin thickening in systemic sclerosis (scleroderma). It’s designed for people whose hand problems are significant but not too severe.
This trial tests a treatment called extracorporeal photopheresis (ECP) for people with early diffuse systemic sclerosis (scleroderma). ECP is a procedure where your blood is treated with light and a medication, then returned to your body, and it may help reduce skin thickening and other symptoms.
This trial tests whether a camera can help people with scleroderma do hand exercises correctly at home, potentially improving hand mobility and daily activities.
This study tests an experimental cell therapy (UTAA91) for people with hard-to-treat scleroderma. The goal is to see if this treatment can help when other options haven't worked.
Hear when a new Scleroderma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.